Anti-S. Epidermidis LTA Recombinant Antibody (Pagibaximab) (CAT#: TAB-H53)

Figure 1 Plasma anti-LTA antibody concentrations over time by pagibaximab dose group on a semilogarithmic axis.

There were seven patients in the 10-mg/kg dose group with data for six patients included on day 56. There were eight patients in the 30-mg/kg dose group with data for seven patients included on day 42 and data for five patients included on day 56. There were eight patients in the 60-mg/kg dose group with data for seven patients included on day 14, day 28, and day 42 and data for six patients included on day 56. There were eight patients in the 90-mg/kg dose group with data for six patients included on day 56.

Weisman, L. E., Thackray, H. M., Garcia-Prats, J. A., Nesin, M., Schneider, J. H., Fretz, J., ... & Fischer, G. W. (2009). Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates. Antimicrobial agents and chemotherapy, 53(7), 2879-2886.

Figure 2 Pagibaximab mean serum concentration, level versus day after infusion for 90 mg/kg (solid) and 60 mg/kg (dashed) groups.

The horizontal solid line represents 500 μg/mL. The day and serum level of staphylococcal-positive blood culture for placebo, 60, and 90 mg/kg groups are represented by a triangle, diamond, and square, respectively.

Weisman, L. E., Thackray, H. M., Steinhorn, R. H., Walsh, W. F., Lassiter, H. A., Dhanireddy, R., ... & Meissner, H. C. (2011). A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis. Pediatrics, 128(2), 271-279.